glp-1 vs insulin Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP1-GIP receptor co-agonists: a promising

Up to 64% of GLP-1 patients discontinue therapy

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Does semaglutide make you tired

GLP-1

Learn how GLP-1 medications impact fertility, like under-eating, potential nutrient deficiencies, and how to manage them.

Key players in Chiles GLP-1 segment: Novo Nordisk Market leader with Ozempic, Victoza, and Wegovy Eli Lilly Bringing innovation with Mounjaro (Tirzepatide) Sanofi Providing Soliqua, a GLP-1 + insulin combo CFR Pharmaceuticals (Abbott) Local affiliate with strong market access Biocon Expanding biosimilar reach in Latam AstraZeneca Strategic focus on metabolic & cardiovascular synergy With increasing physician adoption and patient demand, Chile is evolving into a high-opportunity market for obesity and type 2 diabetes therapies